Happy Chinese New Year for Quintiles as it sets out growth ambitions in Asia
This article was originally published in Scrip
Quintiles has made its Chinese ambitions clear in recent weeks, with the formation of the specialist clinical research subsidiary, Kun Tuo, in Beijing in December (scripclinicalresearch.com, 13 December 2011) and now a new centre in Dalian, a major business hub in northeast China, to provide a range of business process outsourcing and project management services, for clients in Northeast Asian markets.
You may also be interested in...
The road to China's health-care market, once seen to be paved with gold by many medtech companies, is presenting more obstacles than before as a result of increased local competition and challenging policies. Multinationals and start-ups attending the recent China Healthcare Investment Conference discussed ways in which the medtech industry could continue to capitalize on this market's potential.
China is pushing ahead with initiatives in the precision medicine area, where it sees targeted diagnosis and treatment as particularly valuable in areas such as oncology, diabetes and cardiovascular disorders.
The China Food and Drug Administration has released the final version of its biosimilars guideline1.